CAS 37839-81-9|camp sodium salt
| Common Name | camp sodium salt | ||
|---|---|---|---|
| CAS Number | 37839-81-9 | Molecular Weight | 351.19 |
| Density | / | Boiling Point | 701.5ºC at 760 mmHg |
| Molecular Formula | C10H11N5NaO6P | Melting Point | 219 - 220ºC |
| MSDS | / | Flash Point | 378ºC |
Names
| Name | 3',5'-cAMP Na Hydrate |
|---|---|
| Synonym | More Synonyms |
camp sodium salt BiologicalActivity
| Description | Cyclic AMP (Cyclic adenosine monophosphate) sodium, adenosine triphosphate derivative, is an intracellular signaling molecule responsible for directing cellular responses to extracellular signals. Cyclic AMP sodium is an important second messenger in many biological processes[1][2][3]. |
|---|---|
| Related Catalog | Research Areas >>CancerResearch Areas >>Metabolic DiseaseResearch Areas >>Neurological Disease |
| Target | Human Endogenous Metabolite Microbial Metabolite |
| In Vitro | Cyclic AMP (Cyclic adenosine monophosphate) sodium modulates mediator generation. Cyclic AMP sodium suppresses the expression of pro-inflammatory cytokines, including TNF-α and IL-12, and enhances the production of the anti-inflammatory cytokine IL-10. |
| References | [1]. G M Fimia, et al. Cyclic AMP signaling. J Cell Sci. 2001 Jun;114(Pt 11):1971-2. [2]. Paolo Sassone-Corsi, et al. The cyclic AMP pathway. Cold Spring Harb Perspect Biol. 2012 Dec 1;4(12):a011148. [3]. Aronoff DM, et, al. Short communication: differences between macrophages and dendritic cells in the cyclic AMP-dependent regulation of lipopolysaccharide-induced cytokine and chemokine synthesis. J Interferon Cytokine Res. 2006 Nov;26(11):827-33. |
Chemical & Physical Properties
| Boiling Point | 701.5ºC at 760 mmHg |
|---|---|
| Melting Point | 219 - 220ºC |
| Molecular Formula | C10H11N5NaO6P |
| Molecular Weight | 351.19 |
| Flash Point | 378ºC |
| Exact Mass | 351.034454 |
| PSA | 167.48000 |
| LogP | 0.20200 |
| InChIKey | QJOMQLIYJMMGDA-MCDZGGTQSA-N |
| SMILES | Nc1ncnc2c1ncn2C1OC2COP(=O)(O)OC2C1O.[Na] |
| Storage condition | −20°C |
| Water Solubility | H2O: 50 mg/mL | Soluble in water (50 mg/ml). |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 14300 mg/kg
- TOXIC EFFECTS :
- Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity) Gastrointestinal - other changes
- REFERENCE :
- JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 1(2),15,1976
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 395 mg/kg
- TOXIC EFFECTS :
- Behavioral - altered sleep time (including change in righting reflex) Behavioral - tremor Behavioral - ataxia
- REFERENCE :
- JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 1(2),15,1976
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 645 mg/kg
- TOXIC EFFECTS :
- Behavioral - altered sleep time (including change in righting reflex) Behavioral - tremor Behavioral - ataxia
- REFERENCE :
- JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 1(2),15,1976
Safety Information
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Hazard Codes | Xi |
| Risk Phrases | R36/37/38 |
| Safety Phrases | 26-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 2 |
| RTECS | AU7357900 |
| HS Code | 29349990 |
Articles154
More Articles| H4 histamine receptors inhibit steroidogenesis and proliferation in Leydig cells. J. Endocrinol. 223(3) , 241-53, (2014) The histamine H4 receptor (HRH4), discovered only 13 years ago, is considered a promising drug target for allergy, inflammation, autoimmune disorders and cancer, as reflected by a steadily growing num... | |
| HBCDD-induced sustained reduction in mitochondrial membrane potential, ATP and steroidogenesis in peripubertal rat Leydig cells. Toxicol. Appl. Pharmacol. 282(1) , 20-9, (2015) Hexabromocyclododecane (HBCDD), a brominated flame retardant added to various consumer products, is a ubiquitous environmental contaminant. We have previously shown that 6-hour exposure to HBCDD distu... | |
| Activation of cAMP signaling attenuates impaired hepatic glucose disposal in aged male p21-activated protein kinase-1 knockout mice. Endocrinology 155(6) , 2122-32, (2014) p21-activated protein kinase-1 (Pak1) plays a role in insulin secretion and glucagon-like peptide-1 (GLP-1) production. Pak1(-/-) mice were found to carry a defect in ip pyruvate tolerance test (IPPTT... |
Synonyms
| 4H-Furo[3,2-d]-1,3,2-dioxaphosphorin-7-ol, 6-(6-amino-9H-purin-9-yl)tetrahydro-2-hydroxy-, 2-oxide, sodium salt, (4aR,6R,7R,7aS)- (1:1) |
| Adenosine 3',5'-cyclic monophosphate sodium salt monohydrate |
| 3’,5‘-Cyclic AMP sodium salt |
| Adenosine 3',5'-Cyclic Monophosphate Sodium Salt Hydrate |
| Sodium (4aR,6R,7R,7aS)-6-(6-amino-9H-purin-9-yl)-7-hydroxytetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-olate 2-oxide |
| 3',5'-Cyclic AMP Sodium Salt Hydrate |
| Adenosine 3’,5‘-cyclic monophosphate sodium salt monohydrate |
| MFCD00069736 |
| CAMP SODIUM SALT |
